Cargando…
Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics
Prostate cancer (PCa) is the most frequently diagnosed cancer worldwide and the second most common cause of cancer-related deaths among men. Progress in molecular imaging has magnified its clinical management; however, an unmet clinical need involves the identification of new imaging biomarkers that...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047910/ https://www.ncbi.nlm.nih.gov/pubmed/36980482 http://dx.doi.org/10.3390/diagnostics13061175 |
_version_ | 1785014045346103296 |
---|---|
author | Laudicella, Riccardo Spataro, Alessandro Crocè, Ludovica Giacoppo, Giulia Romano, Davide Davì, Valerio Lopes, Maria Librando, Maria Nicocia, Antonio Rappazzo, Andrea Celesti, Greta Torre, Flavia La Pagano, Benedetta Garraffa, Giuseppe Bauckneht, Matteo Burger, Irene A Minutoli, Fabio Baldari, Sergio |
author_facet | Laudicella, Riccardo Spataro, Alessandro Crocè, Ludovica Giacoppo, Giulia Romano, Davide Davì, Valerio Lopes, Maria Librando, Maria Nicocia, Antonio Rappazzo, Andrea Celesti, Greta Torre, Flavia La Pagano, Benedetta Garraffa, Giuseppe Bauckneht, Matteo Burger, Irene A Minutoli, Fabio Baldari, Sergio |
author_sort | Laudicella, Riccardo |
collection | PubMed |
description | Prostate cancer (PCa) is the most frequently diagnosed cancer worldwide and the second most common cause of cancer-related deaths among men. Progress in molecular imaging has magnified its clinical management; however, an unmet clinical need involves the identification of new imaging biomarkers that complement the gold standard of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in cases of clinically significant PCa that do not express PSMA. Fibroblast activation protein (FAP) is a type II transmembrane serine overexpressed in many solid cancers that can be imaged through quinoline-based PET tracers derived from an FAP inhibitor (FAPi). Preliminary results of FAPi application in PCa (in PSMA-negative lesions, and in comparison with fluorodeoxyglucose—FDG) are now available in the literature. FAP-targeting ligands for PCa are not limited to detection, but could also include therapeutic applications. In this preliminary review, we provide an overview of the clinical applications of FAPi ligands in PCa, summarising the main results and highlighting contemporary strengths and limitations. |
format | Online Article Text |
id | pubmed-10047910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100479102023-03-29 Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics Laudicella, Riccardo Spataro, Alessandro Crocè, Ludovica Giacoppo, Giulia Romano, Davide Davì, Valerio Lopes, Maria Librando, Maria Nicocia, Antonio Rappazzo, Andrea Celesti, Greta Torre, Flavia La Pagano, Benedetta Garraffa, Giuseppe Bauckneht, Matteo Burger, Irene A Minutoli, Fabio Baldari, Sergio Diagnostics (Basel) Review Prostate cancer (PCa) is the most frequently diagnosed cancer worldwide and the second most common cause of cancer-related deaths among men. Progress in molecular imaging has magnified its clinical management; however, an unmet clinical need involves the identification of new imaging biomarkers that complement the gold standard of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in cases of clinically significant PCa that do not express PSMA. Fibroblast activation protein (FAP) is a type II transmembrane serine overexpressed in many solid cancers that can be imaged through quinoline-based PET tracers derived from an FAP inhibitor (FAPi). Preliminary results of FAPi application in PCa (in PSMA-negative lesions, and in comparison with fluorodeoxyglucose—FDG) are now available in the literature. FAP-targeting ligands for PCa are not limited to detection, but could also include therapeutic applications. In this preliminary review, we provide an overview of the clinical applications of FAPi ligands in PCa, summarising the main results and highlighting contemporary strengths and limitations. MDPI 2023-03-19 /pmc/articles/PMC10047910/ /pubmed/36980482 http://dx.doi.org/10.3390/diagnostics13061175 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Laudicella, Riccardo Spataro, Alessandro Crocè, Ludovica Giacoppo, Giulia Romano, Davide Davì, Valerio Lopes, Maria Librando, Maria Nicocia, Antonio Rappazzo, Andrea Celesti, Greta Torre, Flavia La Pagano, Benedetta Garraffa, Giuseppe Bauckneht, Matteo Burger, Irene A Minutoli, Fabio Baldari, Sergio Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics |
title | Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics |
title_full | Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics |
title_fullStr | Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics |
title_full_unstemmed | Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics |
title_short | Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics |
title_sort | preliminary findings of the role of fapi in prostate cancer theranostics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047910/ https://www.ncbi.nlm.nih.gov/pubmed/36980482 http://dx.doi.org/10.3390/diagnostics13061175 |
work_keys_str_mv | AT laudicellariccardo preliminaryfindingsoftheroleoffapiinprostatecancertheranostics AT spataroalessandro preliminaryfindingsoftheroleoffapiinprostatecancertheranostics AT croceludovica preliminaryfindingsoftheroleoffapiinprostatecancertheranostics AT giacoppogiulia preliminaryfindingsoftheroleoffapiinprostatecancertheranostics AT romanodavide preliminaryfindingsoftheroleoffapiinprostatecancertheranostics AT davivalerio preliminaryfindingsoftheroleoffapiinprostatecancertheranostics AT lopesmaria preliminaryfindingsoftheroleoffapiinprostatecancertheranostics AT librandomaria preliminaryfindingsoftheroleoffapiinprostatecancertheranostics AT nicociaantonio preliminaryfindingsoftheroleoffapiinprostatecancertheranostics AT rappazzoandrea preliminaryfindingsoftheroleoffapiinprostatecancertheranostics AT celestigreta preliminaryfindingsoftheroleoffapiinprostatecancertheranostics AT torreflaviala preliminaryfindingsoftheroleoffapiinprostatecancertheranostics AT paganobenedetta preliminaryfindingsoftheroleoffapiinprostatecancertheranostics AT garraffagiuseppe preliminaryfindingsoftheroleoffapiinprostatecancertheranostics AT baucknehtmatteo preliminaryfindingsoftheroleoffapiinprostatecancertheranostics AT burgerirenea preliminaryfindingsoftheroleoffapiinprostatecancertheranostics AT minutolifabio preliminaryfindingsoftheroleoffapiinprostatecancertheranostics AT baldarisergio preliminaryfindingsoftheroleoffapiinprostatecancertheranostics |